Hemo Organic submits unaudited standalone financial results

19 Mar 2024 Evaluate
Hemo Organic has informed that it submitted unaudited standalone financial results along with limited review report for the quarter ended on December 31, 2023 on February 12, 2024. However, due to typo graphical error in limited review report, the reporting period was mentioned as December, 2024 instead of December, 2023. Therefore, it attached revised Unaudited standalone limited review report for the quarter ended on December 31, 2023, to rectify the typo graphical error occurred in the period mentioned in limited review report December, 2024 instead of December, 2023. Further, there is no change in data provided earlier except period mentioned in the limited review report. In this regard, it submitted Revised Limited Review Report for the quarter ended on December 31, 2023.

The above information is a part of company’s filings submitted to BSE.

Hemo Organic Share Price

14.53 0.69 (4.99%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×